Biomarkets on the move. February 2013

Biomarkets on the move. February 2013

- Pozen presents positive Phase III data at stroke conference.
- GSK files MAA with EMA for trametinib as monotherapy and in combo with dabrafenib for metastatic melanoma.
- Addex Therapeutics to refocus pipeline, structure Geneva operations.
- Germany’s Federal Joint Committee says Vertex’s Kalydeco provides significant benefit.
- Acceleron’s eight Phase II trials.
- Lilly discontinues tabalumab for rheumatoid arthritis.
- €196 M pan-European drug discovery platform launched.
- Elan, Biogen Idec ink $3.25 B deal for MS drug Tysabri.

[Read more...]